Next Article in Journal
Autographa Californica Multiple Nucleopolyhedrovirus Enters Host Cells via Clathrin-Mediated Endocytosis and Direct Fusion with the Plasma Membrane
Next Article in Special Issue
Development and Characterization of Double-Antibody Sandwich ELISA for Detection of Zika Virus Infection
Previous Article in Journal
ISG15, a Small Molecule with Huge Implications: Regulation of Mitochondrial Homeostasis
Previous Article in Special Issue
Persistence and Intra-Host Genetic Evolution of Zika Virus Infection in Symptomatic Adults: A Special View in the Male Reproductive System
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Viruses 2018, 10(11), 631;

Recent Advances in Zika Virus Vaccines

Center of Emphasis in Infectious Diseases, Department of Biomedical Science, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
Authors to whom correspondence should be addressed.
Received: 16 October 2018 / Revised: 8 November 2018 / Accepted: 11 November 2018 / Published: 14 November 2018
(This article belongs to the Special Issue New Advances on Zika Virus Research)
Full-Text   |   PDF [406 KB, uploaded 14 November 2018]   |  


The recent outbreaks of Zika virus (ZIKV) infections and associated microcephaly in newborns has resulted in an unprecedented effort by researchers to target this virus. Significant advances have been made in developing vaccine candidates, treatment strategies and diagnostic assays in a relatively short period of time. Being a preventable disease, the first line of defense against ZIKV would be to vaccinate the highly susceptible target population, especially pregnant women. Along those lines, several vaccine candidates including purified inactivated virus (PIV), live attenuated virus (LAV), virus like particles (VLP), DNA, modified RNA, viral vectors and subunit vaccines have been in the pipeline with several advancing to clinical trials. As the primary objective of Zika vaccination is the prevention of vertical transmission of the virus to the unborn fetus, the safety and efficacy requirements for this vaccine remain unique when compared to other diseases. This review will discuss these recent advances in the field of Zika vaccine development. View Full-Text
Keywords: Zika virus; flaviviruses; vaccines; virus like particles; clinical trials; ZIKV Zika virus; flaviviruses; vaccines; virus like particles; clinical trials; ZIKV

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Garg, H.; Mehmetoglu-Gurbuz, T.; Joshi, A. Recent Advances in Zika Virus Vaccines. Viruses 2018, 10, 631.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top